24638-29-7

Basic information

• Product Name: 2,3-Diamino-5-methylpyridine
• Synonyms: 2,3-Diamino-5-methylpyridine;2,3-Diamino-5-methylpyridnie;3-Picoline,5,6-diamino- (8CI);5-Methyl-2,3-pyridinediamine;5-Methyl-2,3-diaMinopyridine
• CAS NO: 24638-29-7
• Molecular Formula: C₆H₉N₃
• Molecular Weight: 123.16
• Product Categories: Heterocycle-Pyridine series
• Mol File: 24638-29-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 315.761 °C at 760 mmHg
• Flash Point: 170.583 °C
• Appearance: /
• Density: 1.19 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.648
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 2,3-Diamino-5-methylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-Diamino-5-methylpyridine(24638-29-7)
• EPA Substance Registry System: 2,3-Diamino-5-methylpyridine(24638-29-7)

Safety Data

• Hazardous Substances Data: 24638-29-7(Hazardous Substances Data)

Usage

General Description

2,3-Diamino-5-methylpyridine is a chemical compound with the molecular formula C6H9N3. It is a pyridine derivative that consists of a pyridine ring substituted with amino and methyl groups at the 2 and 5 positions, respectively. 2,3-Diamino-5-methylpyridine is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. It is also utilized in the production of dyes, pigments, and other organic compounds. Additionally, 2,3-Diamino-5-methylpyridine has been studied for its potential biological activities and therapeutic applications, particularly in the treatment of cancer and other diseases. However, it is important to handle this chemical with caution, as it may pose health risks if not used properly.

InChI:InChI=1/C6H9N3/c1-4-2-5(7)6(8)9-3-4/h2-3H,7H2,1H3,(H2,8,9)

Upstream product

• 7598-26-7 5-Methyl-3-nitro-2-aminopyridine 
• 1603-41-4 (5-methyl-pyridin-2-yl)amine 

Downstream Products

• 127356-25-6 2-(2-Methoxy-4-methylsulfanyl-phenyl)-6-methyl-1H-imidazo[4,5-b]pyridine 
• 107238-22-2 2-(4-Methanesulfinyl-2-methoxy-phenyl)-6-methyl-1H-imidazo[4,5-b]pyridine 

Relevant articles and documents

Optimization of 5-substituted thiazolyl ureas and 6-substituted imidazopyridines as potential HIV-1 latency reversing agents

A persistent latent reservoir of virus in CD4+ T cells is a major barrier to cure HIV. Activating viral transcription in latently infected cells using small molecules is one strategy being explored to eliminate latency. We previously described the use of a FlpIn.FM HEK293 cellular assay to identify and then optimize the 2-acylaminothiazole class to exhibit modest activation of HIV gene expression. Here, we implement two strategies to further improve the activation of viral gene expression and physicochemical properties of this class. Firstly, we explored rigidification of the central oxy-carbon linker with a variety of saturated heterocycles, and secondly, investigated bioisosteric replacement of the 2-acylaminothiazole moiety. The optimization process afforded lead compounds (74 and 91) from the 2-piperazinyl thiazolyl urea and the imidazopyridine class. The lead compounds from each class demonstrate potent activation of HIV gene expression in the FlpIn.FM HEK293 cellular assay (both with LTR EC50s of 80 nM) and in the Jurkat Latency 10.6 cell model (LTR EC50 220 and 320 nM respectively), but consequently activate gene expression non-specifically in the FlpIn.FM HEK293 cellular assay (CMV EC50 70 and 270 nM respectively) manifesting in cellular cytotoxicity. The lead compounds have potential for further development as novel latency reversing agents.

ACTIVATORS OF HIV LATENCY

The present invention relates to novel compounds which active HIV expression in latently infected cells. More particularly, the invention relates to pharmaceutical compositions comprising the novel compounds and their use in activating HIV expression in latently infected cells. Further still, the invention relates to pharmaceutical compositions comprising the novel compounds in combination with anti-HIV therapy compounds and their use in treating HIV infection in both animals and humans. The invention further provides means for preparing the compounds.

4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes

The invention relates to 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalene derivatives of general formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.